HZNP Horizon Therapeutics Public Limited Company

30.01
+0.51  (+2%)
Previous Close 29.5
Open 29.55
Price To Book 3.61
Market Cap 5,620,939,892
Shares 187,302,229
Volume 1,515,445
Short Ratio
Av. Daily Volume 1,213,082
Stock charts supplied by TradingView

NewsSee all news

  1. Data from Uncontrolled Gout Case Series Supports Immunomodulation with KRYSTEXXA® (pegloticase injection) Strategy to Optimize Treatment Outcomes

    -- Horizon data at American College of Rheumatology Annual Meeting also cite the need for vigilance in treating gout among kidney transplant recipients -- Horizon Therapeutics plc (NASDAQ:HZNP) today announced the

  2. The Chicago Tribune Names Horizon Therapeutics plc a 2019 Top Workplace

    Horizon Therapeutics plc (NASDAQ:HZNP) has been awarded a Top Workplaces 2019 honor by the Chicago Tribune. This is the fifth consecutive year Horizon has received this honor. "We take tremendous pride in being named

  3. Horizon Therapeutics plc Brings Gout-Kidney Link into Focus during American Society of Nephrology (ASN) Kidney Week 2019

    - Research, interactive features and charitable opportunity support advancement of care - Horizon Therapeutics plc (NASDAQ:HZNP) will join the leading voices in the nephrology community this week to inform and build

  4. Clinical Study Data Highlighting the Impact of Teprotumumab in Patients With Active Thyroid Eye Disease to Be Presented During ACR Annual Meeting

    Horizon Therapeutics plc (NASDAQ:HZNP) today announced an integrated analysis of efficacy data from the Phase 2 and Phase 3 clinical trials of teprotumumab will be presented during an oral session at the American

  5. New Evidence on the Burden of Gout to be Featured in Data Presentations at Upcoming ACR Annual Meeting

    -- Data to be presented from in-practice clinician case series on novel immunomodulation strategy -- Horizon Therapeutics plc (NASDAQ:HZNP) today announced multiple presentations that will highlight the serious,

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 3 data released December 8, 2016 - primary endpoint not met.
ACTIMMUNE
Friedreich's Ataxia (FA)
Phase 2 trial initiation announced September 27, 2018.
Krystexxa with Methotrexate
Gout
Randomized trial initiation announced June 20, 2019.
Krystexxa with Methotrexate - MIRROR RCT
Gout
PDUFA date under priority review March 8, 2020.
Teprotumumab
Thyroid Eye Disease (TED)

Latest News

  1. Data from Uncontrolled Gout Case Series Supports Immunomodulation with KRYSTEXXA® (pegloticase injection) Strategy to Optimize Treatment Outcomes

    -- Horizon data at American College of Rheumatology Annual Meeting also cite the need for vigilance in treating gout among kidney transplant recipients -- Horizon Therapeutics plc (NASDAQ:HZNP) today announced the

  2. The Chicago Tribune Names Horizon Therapeutics plc a 2019 Top Workplace

    Horizon Therapeutics plc (NASDAQ:HZNP) has been awarded a Top Workplaces 2019 honor by the Chicago Tribune. This is the fifth consecutive year Horizon has received this honor. "We take tremendous pride in being named

  3. Horizon Therapeutics plc Brings Gout-Kidney Link into Focus during American Society of Nephrology (ASN) Kidney Week 2019

    - Research, interactive features and charitable opportunity support advancement of care - Horizon Therapeutics plc (NASDAQ:HZNP) will join the leading voices in the nephrology community this week to inform and build

  4. Clinical Study Data Highlighting the Impact of Teprotumumab in Patients With Active Thyroid Eye Disease to Be Presented During ACR Annual Meeting

    Horizon Therapeutics plc (NASDAQ:HZNP) today announced an integrated analysis of efficacy data from the Phase 2 and Phase 3 clinical trials of teprotumumab will be presented during an oral session at the American

  5. New Evidence on the Burden of Gout to be Featured in Data Presentations at Upcoming ACR Annual Meeting

    -- Data to be presented from in-practice clinician case series on novel immunomodulation strategy -- Horizon Therapeutics plc (NASDAQ:HZNP) today announced multiple presentations that will highlight the serious,

  6. Integrated Clinical Trial Analyses Further Substantiate that Teprotumumab Significantly Improves Debilitating Effects of Thyroid Eye Disease, Including Eye Bulging, Double Vision and Quality of Life

    Horizon Therapeutics plc (NASDAQ:HZNP) today announced integrated, pooled efficacy data from the Phase 2 and Phase 3 clinical trials of teprotumumab for the treatment of active thyroid eye disease (TED) compared to

  7. Horizon Therapeutics plc Named One of the Most Innovative Companies by Crain's Chicago Business

    Horizon Therapeutics plc (NASDAQ:HZNP) today announced that it is has been named one of the Most Innovative Companies in Chicago by Crain's Chicago Business, ranking number two. Crain's compiles the list based on a

  8. AVISE® MTX Test from Exagen Supports Horizon Therapeutics plc Clinical Trial to Evaluate Pegloticase with Methotrexate to Enhance Response Rates for People Living with Uncontrolled Gout

    SAN DIEGO, Oct. 24, 2019 (GLOBE NEWSWIRE) -- Exagen Inc. (NASDAQ:XGN), is pleased to announce clinical study support for Horizon Therapeutics plc (NASDAQ:HZNP) to measure methotrexate polyglutamates (MTXPGs), the

  9. New Data from Teprotumumab Phase 3 OPTIC Study Shows Significantly Reduced Double Vision and Improved Quality of Life for People with Active Thyroid Eye Disease

    Horizon Therapeutics plc (NASDAQ:HZNP) today announced new data from the Phase 3 OPTIC confirmatory clinical trial showing that teprotumumab provided significant benefit on several devastating effects of active thyroid

  10. For World Sight Day, Horizon and Prevent Blindness Are Calling on the Thyroid Eye Disease (TED) Community to Put "Vision First"

    -- Text the word "EYE" to 56512 to generate a donation from Horizon to Prevent Blindness to fund TED education -- Today, in support of World Sight Day, Horizon Therapeutics plc (NASDAQ:HZNP) and Prevent Blindness

  11. Horizon Therapeutics plc to Release Third-Quarter 2019 Financial Results and Host Webcast on Nov. 6, 2019

    Horizon Therapeutics plc (NASDAQ:HZNP) announced today that its third-quarter 2019 financial results will be released on Wednesday, Nov. 6, 2019. Following the announcement, Horizon's management will host a live

  12. New Data Insights from the Phase 3 Teprotumumab Trial (OPTIC) to be Presented at the American Society of Ophthalmic Plastic and Reconstructive Surgery (ASOPRS) Scientific Symposium

    Additional results from the Phase 3 confirmatory clinical trial (OPTIC) of teprotumumab, an investigational medicine being developed by Horizon Therapeutics plc, will be presented at the American Society of Ophthalmic

  13. Horizon Therapeutics plc Named One of the Best Adoption-Friendly Workplaces by the Dave Thomas Foundation for Adoption

    Horizon Therapeutics plc (NASDAQ:HZNP) today announced that it has been named one of the top 100 adoption-friendly workplaces in the country by the Dave Thomas Foundation for Adoption, ranking number 56 overall and

  14. Horizon Therapeutics plc Announces the FDA has Granted Priority Review of the Teprotumumab Biologics License Application (BLA) for the Treatment of Active Thyroid Eye Disease (TED)

    -- If Approved, Teprotumumab Would be the First FDA-Approved Medicine for this Vision-Threatening Disease -- Horizon Therapeutics plc (NASDAQ:HZNP) today announced that the U.S. Food and Drug Administration (FDA) has

  15. Horizon Therapeutics plc Names Andy Pasternak Executive Vice President, Chief Business Officer

    - Current Executive Vice President and Chief Business Officer, Robert F. Carey, will Retire Effective Oct. 1. - DUBLIN – August 28, 2019 – Horizon Therapeutics plc (NASDAQ:HZNP) today named Andy Pasternak executive